TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

Global and United States Oncology Biosimilars Market Report & Forecast 2022-2028

Global and United States Oncology Biosimilars Market Report & Forecast 2022-2028

  • Category:Life Sciences
  • Published on : 08 October 2022
  • Pages :102
  • Formats:
  • Report Code:SMR-7423240
OfferClick for best price

Best Price: $3480

Oncology Biosimilars Market Size, Share 2022


Market Analysis and Insights: Global Oncology Biosimilars Market

The global Oncology Biosimilars market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Oncology Biosimilars market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Oncology Biosimilars market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Oncology Biosimilars market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Oncology Biosimilars market.

Global Oncology Biosimilars Scope and Market Size

Oncology Biosimilars market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Oncology Biosimilars market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the Oncology Biosimilars market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type

Monoclonal Antibody

Hematopoietic Agents

G-CSF

Others

Segment by Application

Retail Pharmacies

Hospital Pharmacy

Online Pharmacy

By Region

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Indonesia

Thailand

Malaysia

Philippines

Vietnam

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

U.A.E

By Company

Celltrion

Biocon

Dr. Reddy?s Laboratories

STADA Arzneimittel AG

Intas Pharmaceuticals

Pfizer

Sandoz International

Teva Pharmaceutical Industries Ltd

Apotex

BIOCAD

The information for each competitor/Company Profile includes:

  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis 

The content of the study subjects includes a total of 15 chapters:

Chapter 1, describes Oncology Biosimilars product scope, market overview, market opportunities, market driving force, and market risks.

Chapter 2, profiles the top manufacturers of Oncology Biosimilars, with price, sales, revenue, and global market share of Oncology Biosimilars from 2019 to 2022.

Chapter 3, the Oncology Biosimilars competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Oncology Biosimilars breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.

Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Oncology Biosimilars market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of Oncology Biosimilars.

Chapter 13, 14, and 15, to describe Oncology Biosimilars sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Key Indicators Analysed:

  • Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
  • Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
  • Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
  • Opportunities and Drivers: Identifying the Growing Demands and New Technology
  • Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Reasons to Purchase this Report:

  • Estimates 2022-2027 2021-2025 Oncology Biosimilars Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
  • Market dynamics scenario, along with growth opportunities of the market in the years to come
  • Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
  • Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
  • Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
  • Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • 1-year analyst support, along with the data support in excel format.

Research Methodology:

The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Report Attributes Report Details
Report Title Global and United States Oncology Biosimilars Market Report & Forecast 2022-2028
Historical Year 2018 to 2022 (Data from 2010 can be provided as per availability)
Base Year 2021
Forecast Year 2029
Number of Pages 102 Pages
Customization Available Yes, the report can be customized as per your need.

TABLE OF CONTENTS

1 Study Coverage
1.1 Oncology Biosimilars Product Introduction
1.2 Global Oncology Biosimilars Outlook 2017 VS 2022 VS 2028
1.2.1 Global Oncology Biosimilars Sales in US$ Million for the Year 2017-2028
1.2.2 Global Oncology Biosimilars Sales in Volume for the Year 2017-2028
1.3 United States Oncology Biosimilars Outlook 2017 VS 2022 VS 2028
1.3.1 United States Oncology Biosimilars Sales in US$ Million for the Year 2017-2028
1.3.2 United States Oncology Biosimilars Sales in Volume for the Year 2017-2028
1.4 Oncology Biosimilars Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States Oncology Biosimilars in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of Oncology Biosimilars Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 Oncology Biosimilars Market Dynamics
1.5.1 Oncology Biosimilars Industry Trends
1.5.2 Oncology Biosimilars Market Drivers
1.5.3 Oncology Biosimilars Market Challenges
1.5.4 Oncology Biosimilars Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 Oncology Biosimilars Market Segment by Type
2.1.1 Monoclonal Antibody
2.1.2 Hematopoietic Agents
2.1.3 G-CSF
2.1.4 Others
2.2 Global Oncology Biosimilars Market Size by Type
2.2.1 Global Oncology Biosimilars Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global Oncology Biosimilars Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global Oncology Biosimilars Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States Oncology Biosimilars Market Size by Type
2.3.1 United States Oncology Biosimilars Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States Oncology Biosimilars Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States Oncology Biosimilars Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 Oncology Biosimilars Market Segment by Application
3.1.1 Retail Pharmacies
3.1.2 Hospital Pharmacy
3.1.3 Online Pharmacy
3.2 Global Oncology Biosimilars Market Size by Application
3.2.1 Global Oncology Biosimilars Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global Oncology Biosimilars Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global Oncology Biosimilars Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States Oncology Biosimilars Market Size by Application
3.3.1 United States Oncology Biosimilars Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States Oncology Biosimilars Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States Oncology Biosimilars Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global Oncology Biosimilars Competitor Landscape by Company
4.1 Global Oncology Biosimilars Market Size by Company
4.1.1 Top Global Oncology Biosimilars Manufacturers Ranked by Revenue (2021)
4.1.2 Global Oncology Biosimilars Revenue by Manufacturer (2017-2022)
4.1.3 Global Oncology Biosimilars Sales by Manufacturer (2017-2022)
4.1.4 Global Oncology Biosimilars Price by Manufacturer (2017-2022)
4.2 Global Oncology Biosimilars Concentration Ratio (CR)
4.2.1 Oncology Biosimilars Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Oncology Biosimilars in 2021
4.2.3 Global Oncology Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Oncology Biosimilars Manufacturing Base Distribution, Product Type
4.3.1 Global Oncology Biosimilars Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers Oncology Biosimilars Product Type
4.3.3 Date of International Manufacturers Enter into Oncology Biosimilars Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States Oncology Biosimilars Market Size by Company
4.5.1 Top Oncology Biosimilars Players in United States, Ranked by Revenue (2021)
4.5.2 United States Oncology Biosimilars Revenue by Players (2020, 2021 & 2022)
4.5.3 United States Oncology Biosimilars Sales by Players (2020, 2021 & 2022)
5 Global Oncology Biosimilars Market Size by Region
5.1 Global Oncology Biosimilars Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Oncology Biosimilars Market Size in Volume by Region (2017-2028)
5.2.1 Global Oncology Biosimilars Sales in Volume by Region: 2017-2022
5.2.2 Global Oncology Biosimilars Sales in Volume Forecast by Region (2023-2028)
5.3 Global Oncology Biosimilars Market Size in Value by Region (2017-2028)
5.3.1 Global Oncology Biosimilars Sales in Value by Region: 2017-2022
5.3.2 Global Oncology Biosimilars Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Oncology Biosimilars Market Size YoY Growth 2017-2028
6.1.2 North America Oncology Biosimilars Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Oncology Biosimilars Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Oncology Biosimilars Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Oncology Biosimilars Market Size YoY Growth 2017-2028
6.3.2 Europe Oncology Biosimilars Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Oncology Biosimilars Market Size YoY Growth 2017-2028
6.4.2 Latin America Oncology Biosimilars Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Oncology Biosimilars Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Oncology Biosimilars Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Celltrion
7.1.1 Celltrion Corporation Information
7.1.2 Celltrion Description and Business Overview
7.1.3 Celltrion Oncology Biosimilars Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Celltrion Oncology Biosimilars Products Offered
7.1.5 Celltrion Recent Development
7.2 Biocon
7.2.1 Biocon Corporation Information
7.2.2 Biocon Description and Business Overview
7.2.3 Biocon Oncology Biosimilars Sales, Revenue and Gross Margin (2017-2022)
7.2.4 Biocon Oncology Biosimilars Products Offered
7.2.5 Biocon Recent Development
7.3 Dr. Reddy?s Laboratories
7.3.1 Dr. Reddy?s Laboratories Corporation Information
7.3.2 Dr. Reddy?s Laboratories Description and Business Overview
7.3.3 Dr. Reddy?s Laboratories Oncology Biosimilars Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Dr. Reddy?s Laboratories Oncology Biosimilars Products Offered
7.3.5 Dr. Reddy?s Laboratories Recent Development
7.4 STADA Arzneimittel AG
7.4.1 STADA Arzneimittel AG Corporation Information
7.4.2 STADA Arzneimittel AG Description and Business Overview
7.4.3 STADA Arzneimittel AG Oncology Biosimilars Sales, Revenue and Gross Margin (2017-2022)
7.4.4 STADA Arzneimittel AG Oncology Biosimilars Products Offered
7.4.5 STADA Arzneimittel AG Recent Development
7.5 Intas Pharmaceuticals
7.5.1 Intas Pharmaceuticals Corporation Information
7.5.2 Intas Pharmaceuticals Description and Business Overview
7.5.3 Intas Pharmaceuticals Oncology Biosimilars Sales, Revenue and Gross Margin (2017-2022)
7.5.4 Intas Pharmaceuticals Oncology Biosimilars Products Offered
7.5.5 Intas Pharmaceuticals Recent Development
7.6 Pfizer
7.6.1 Pfizer Corporation Information
7.6.2 Pfizer Description and Business Overview
7.6.3 Pfizer Oncology Biosimilars Sales, Revenue and Gross Margin (2017-2022)
7.6.4 Pfizer Oncology Biosimilars Products Offered
7.6.5 Pfizer Recent Development
7.7 Sandoz International
7.7.1 Sandoz International Corporation Information
7.7.2 Sandoz International Description and Business Overview
7.7.3 Sandoz International Oncology Biosimilars Sales, Revenue and Gross Margin (2017-2022)
7.7.4 Sandoz International Oncology Biosimilars Products Offered
7.7.5 Sandoz International Recent Development
7.8 Teva Pharmaceutical Industries Ltd
7.8.1 Teva Pharmaceutical Industries Ltd Corporation Information
7.8.2 Teva Pharmaceutical Industries Ltd Description and Business Overview
7.8.3 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Sales, Revenue and Gross Margin (2017-2022)
7.8.4 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Products Offered
7.8.5 Teva Pharmaceutical Industries Ltd Recent Development
7.9 Apotex
7.9.1 Apotex Corporation Information
7.9.2 Apotex Description and Business Overview
7.9.3 Apotex Oncology Biosimilars Sales, Revenue and Gross Margin (2017-2022)
7.9.4 Apotex Oncology Biosimilars Products Offered
7.9.5 Apotex Recent Development
7.10 BIOCAD
7.10.1 BIOCAD Corporation Information
7.10.2 BIOCAD Description and Business Overview
7.10.3 BIOCAD Oncology Biosimilars Sales, Revenue and Gross Margin (2017-2022)
7.10.4 BIOCAD Oncology Biosimilars Products Offered
7.10.5 BIOCAD Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 Oncology Biosimilars Industry Chain Analysis
8.2 Oncology Biosimilars Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Oncology Biosimilars Distributors
8.3 Oncology Biosimilars Production Mode & Process
8.4 Oncology Biosimilars Sales and Marketing
8.4.1 Oncology Biosimilars Sales Channels
8.4.2 Oncology Biosimilars Distributors
8.5 Oncology Biosimilars Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

LIST OF TABLES & FIGURES

List of Tables
Table 1. Oncology Biosimilars CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
Table 2. Oncology Biosimilars Market Trends
Table 3. Oncology Biosimilars Market Drivers
Table 4. Oncology Biosimilars Market Challenges
Table 5. Oncology Biosimilars Market Restraints
Table 6. Global Oncology Biosimilars Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 7. United States Oncology Biosimilars Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 8. Global Oncology Biosimilars Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 9. United States Oncology Biosimilars Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 10. Top Oncology Biosimilars Manufacturers in Global Market, Ranking by Revenue (2021)
Table 11. Global Oncology Biosimilars Revenue by Manufacturer, (US$ Million), 2017-2022
Table 12. Global Oncology Biosimilars Revenue Share by Manufacturer, 2017-2022
Table 13. Global Oncology Biosimilars Sales by Manufacturer, (K Units), 2017-2022
Table 14. Global Oncology Biosimilars Sales Share by Manufacturer, 2017-2022
Table 15. Global Oncology Biosimilars Price by Manufacturer (2017-2022) & (US$/Unit)
Table 16. Global Oncology Biosimilars Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Oncology Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncology Biosimilars as of 2021)
Table 18. Top Players of Oncology Biosimilars in Global Market, Headquarters and Distribution of Producing Region
Table 19. Manufacturers Oncology Biosimilars Product Type
Table 20. Date of International Manufacturers Enter into Oncology Biosimilars Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Top Oncology Biosimilars Players in United States Market, Ranking by Revenue (2021)
Table 23. United States Oncology Biosimilars Revenue by Players, (US$ Million), 2020, 2021 & 2022
Table 24. United States Oncology Biosimilars Revenue Share by Players, 2020, 2021 & 2022
Table 25. United States Oncology Biosimilars Sales by Players, (K Units), 2020, 2021 & 2022
Table 26. United States Oncology Biosimilars Sales Share by Players, 2020, 2021 & 2022
Table 27. Global Oncology Biosimilars Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
Table 28. Global Oncology Biosimilars Sales in Volume by Region (2017-2022) & (K Units)
Table 29. Global Oncology Biosimilars Sales in Volume Forecast by Region (2023-2028) & (K Units)
Table 30. Global Oncology Biosimilars Sales in Value by Region (2017-2022) & (US$ Million)
Table 31. Global Oncology Biosimilars Sales in Value Forecast by Region (2023-2028) & (US$ Million)
Table 32. North America Oncology Biosimilars Sales in Volume by Country (2017-2028) & (K Units)
Table 33. North America Oncology Biosimilars Sales in Value by Country (2017-2028) & (US$ Million)
Table 34. Asia Pacific Oncology Biosimilars Sales in Volume by Region (2017-2028) & (K Units)
Table 35. Asia Pacific Oncology Biosimilars Sales in Value by Region (2017-2028) & (US$ Million)
Table 36. Europe Oncology Biosimilars Sales in Volume by Country (2017-2028) & (K Units)
Table 37. Europe Oncology Biosimilars Sales in Value by Country (2017-2028) & (US$ Million)
Table 38. Latin America Oncology Biosimilars Sales in Volume by Country (2017-2028) & (K Units)
Table 39. Latin Americaa Oncology Biosimilars Sales in Value by Country (2017-2028) & (US$ Million)
Table 40. Middle East and Africa Oncology Biosimilars Sales in Volume by Country (2017-2028) & (K Units)
Table 41. Middle East and Africa Oncology Biosimilars Sales in Value by Country (2017-2028) & (US$ Million)
Table 42. Celltrion Corporation Information
Table 43. Celltrion Description and Business Overview
Table 44. Celltrion Oncology Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 45. Celltrion Oncology Biosimilars Product
Table 46. Celltrion Recent Development
Table 47. Biocon Corporation Information
Table 48. Biocon Description and Business Overview
Table 49. Biocon Oncology Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 50. Biocon Product
Table 51. Biocon Recent Development
Table 52. Dr. Reddy?s Laboratories Corporation Information
Table 53. Dr. Reddy?s Laboratories Description and Business Overview
Table 54. Dr. Reddy?s Laboratories Oncology Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 55. Dr. Reddy?s Laboratories Product
Table 56. Dr. Reddy?s Laboratories Recent Development
Table 57. STADA Arzneimittel AG Corporation Information
Table 58. STADA Arzneimittel AG Description and Business Overview
Table 59. STADA Arzneimittel AG Oncology Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 60. STADA Arzneimittel AG Product
Table 61. STADA Arzneimittel AG Recent Development
Table 62. Intas Pharmaceuticals Corporation Information
Table 63. Intas Pharmaceuticals Description and Business Overview
Table 64. Intas Pharmaceuticals Oncology Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 65. Intas Pharmaceuticals Product
Table 66. Intas Pharmaceuticals Recent Development
Table 67. Pfizer Corporation Information
Table 68. Pfizer Description and Business Overview
Table 69. Pfizer Oncology Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 70. Pfizer Product
Table 71. Pfizer Recent Development
Table 72. Sandoz International Corporation Information
Table 73. Sandoz International Description and Business Overview
Table 74. Sandoz International Oncology Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 75. Sandoz International Product
Table 76. Sandoz International Recent Development
Table 77. Teva Pharmaceutical Industries Ltd Corporation Information
Table 78. Teva Pharmaceutical Industries Ltd Description and Business Overview
Table 79. Teva Pharmaceutical Industries Ltd Oncology Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 80. Teva Pharmaceutical Industries Ltd Product
Table 81. Teva Pharmaceutical Industries Ltd Recent Development
Table 82. Apotex Corporation Information
Table 83. Apotex Description and Business Overview
Table 84. Apotex Oncology Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 85. Apotex Product
Table 86. Apotex Recent Development
Table 87. BIOCAD Corporation Information
Table 88. BIOCAD Description and Business Overview
Table 89. BIOCAD Oncology Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 90. BIOCAD Product
Table 91. BIOCAD Recent Development
Table 92. Key Raw Materials Lists
Table 93. Raw Materials Key Suppliers Lists
Table 94. Oncology Biosimilars Customers List
Table 95. Oncology Biosimilars Distributors List
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
List of Figures
Figure 1. Oncology Biosimilars Product Picture
Figure 2. Global Oncology Biosimilars Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 3. Global Oncology Biosimilars Market Size 2017-2028 (US$ Million)
Figure 4. Global Oncology Biosimilars Sales 2017-2028 (K Units)
Figure 5. United States Oncology Biosimilars Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 6. United States Oncology Biosimilars Market Size 2017-2028 (US$ Million)
Figure 7. United States Oncology Biosimilars Sales 2017-2028 (K Units)
Figure 8. United States Oncology Biosimilars Market Share in Global, in Value (US$ Million) 2017-2028
Figure 9. United States Oncology Biosimilars Market Share in Global, in Volume (K Units) 2017-2028
Figure 10. Oncology Biosimilars Report Years Considered
Figure 11. Product Picture of Monoclonal Antibody
Figure 12. Product Picture of Hematopoietic Agents
Figure 13. Product Picture of G-CSF
Figure 14. Product Picture of Others
Figure 15. Global Oncology Biosimilars Market Share by Type in 2022 & 2028
Figure 16. Global Oncology Biosimilars Sales in Value by Type (2017-2028) & (US$ Million)
Figure 17. Global Oncology Biosimilars Sales Market Share in Value by Type (2017-2028)
Figure 18. Global Oncology Biosimilars Sales by Type (2017-2028) & (K Units)
Figure 19. Global Oncology Biosimilars Sales Market Share in Volume by Type (2017-2028)
Figure 20. Global Oncology Biosimilars Price by Type (2017-2028) & (US$/Unit)
Figure 21. United States Oncology Biosimilars Market Share by Type in 2022 & 2028
Figure 22. United States Oncology Biosimilars Sales in Value by Type (2017-2028) & (US$ Million)
Figure 23. United States Oncology Biosimilars Sales Market Share in Value by Type (2017-2028)
Figure 24. United States Oncology Biosimilars Sales by Type (2017-2028) & (K Units)
Figure 25. United States Oncology Biosimilars Sales Market Share in Volume by Type (2017-2028)
Figure 26. United States Oncology Biosimilars Price by Type (2017-2028) & (US$/Unit)
Figure 27. Product Picture of Retail Pharmacies
Figure 28. Product Picture of Hospital Pharmacy
Figure 29. Product Picture of Online Pharmacy
Figure 30. Global Oncology Biosimilars Market Share by Application in 2022 & 2028
Figure 31. Global Oncology Biosimilars Sales in Value by Application (2017-2028) & (US$ Million)
Figure 32. Global Oncology Biosimilars Sales Market Share in Value by Application (2017-2028)
Figure 33. Global Oncology Biosimilars Sales by Application (2017-2028) & (K Units)
Figure 34. Global Oncology Biosimilars Sales Market Share in Volume by Application (2017-2028)
Figure 35. Global Oncology Biosimilars Price by Application (2017-2028) & (US$/Unit)
Figure 36. United States Oncology Biosimilars Market Share by Application in 2022 & 2028
Figure 37. United States Oncology Biosimilars Sales in Value by Application (2017-2028) & (US$ Million)
Figure 38. United States Oncology Biosimilars Sales Market Share in Value by Application (2017-2028)
Figure 39. United States Oncology Biosimilars Sales by Application (2017-2028) & (K Units)
Figure 40. United States Oncology Biosimilars Sales Market Share in Volume by Application (2017-2028)
Figure 41. United States Oncology Biosimilars Price by Application (2017-2028) & (US$/Unit)
Figure 42. North America Oncology Biosimilars Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 43. North America Oncology Biosimilars Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 44. U.S. Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 45. Canada Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 46. Europe Oncology Biosimilars Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 47. Europe Oncology Biosimilars Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 48. Germany Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 49. France Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 50. U.K. Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 51. Italy Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 52. Russia Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 53. Asia-Pacific Oncology Biosimilars Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 54. Asia-Pacific Oncology Biosimilars Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 55. China Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 56. Japan Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 57. South Korea Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 58. India Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 59. Australia Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 60. Taiwan Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 61. Indonesia Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 62. Thailand Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 63. Malaysia Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 64. Philippines Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 65. Latin America Oncology Biosimilars Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 66. Latin America Oncology Biosimilars Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 67. Mexico Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 68. Brazil Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 69. Argentina Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 70. Middle East & Africa Oncology Biosimilars Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 71. Middle East & Africa Oncology Biosimilars Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 72. Turkey Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 73. Saudi Arabia Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 74. U.A.E Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 75. Oncology Biosimilars Value Chain
Figure 76. Oncology Biosimilars Production Process
Figure 77. Channels of Distribution
Figure 78. Distributors Profiles
Figure 79. Bottom-up and Top-down Approaches for This Report
Figure 80. Data Triangulation
Figure 81. Key Executives Interviewed

REPORT PURCHASE OPTIONS

USD Single User Price
USD Multi User Price
USD Enterprise Price

---- OR ----

Frequently Asked Questions ?

  • Upto 24 hrs - Working days
  • Upto 48 hrs max - Weekends and public holidays
  • Single User License
    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License
    A license granted to multiple users.

  • Site License
    A license granted to a single business site/establishment.

  • Corporate License, Global License
    A license granted to all employees within organisation access to the product.
  • Online Payments with PayPal and CCavenue
  • Wire Transfer/Bank Transfer
  • Email
  • Hard Copy

Our Key Features

  • Data Accuracy and Reliability
  • Data Security
  • Customized Research
  • Trustworthy
  • Competitive Offerings
check discount